What is the price-to-earnings ratio of Biogen?
The price-earnings ratio of Biogen is currently 12.87.
Biogen P/E 2024
Biogen P/E
12.87
Biogen Dividend yield
Ticker
BIIB
ISIN
US09062X1037
WKN
789617
As of Apr 26, 2024, Biogen's P/E ratio was 12.87, a -66.06% change from the 37.92 P/E ratio recorded in the previous year.
The Biogen P/E history
Biogen Aktienanalyse
What does Biogen do?
Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future. Biogen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Biogen revenue by segment
In the annual report of the Biogen share (US09062X1037, 789617, BIIB), it breaks down its revenues into 3 segments: 1. Product, 2. Other, 3. Therapeutics. The Biogen stock (WKN: 789617, ISIN: US09062X1037, Ticker Symbol: BIIB) is a leading investment for investors interested in participating in the Health Care sector.
P/E Details
Deciphering Biogen's P/E Ratio
The Price to Earnings (P/E) Ratio of Biogen is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Biogen's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Biogen is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Biogen’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Biogen Stock
How has the price-earnings ratio of Biogen changed compared to last year?
The price-to-earnings ratio of Biogen has increased by -66.06% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Biogen high compared to other companies?
Yes, the price-to-earnings ratio of Biogen is high compared to other companies.
How does an increase in the price-earnings ratio of Biogen affect the company?
An increase in the price-earnings ratio of Biogen would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Biogen affect the company?
A decrease in the price-earnings ratio of Biogen would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Biogen?
Some factors that influence the price-earnings ratio of Biogen are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Biogen pay?
Over the past 12 months, Biogen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biogen is expected to pay a dividend of 0 USD.
What is the dividend yield of Biogen?
The current dividend yield of Biogen is .
When does Biogen pay dividends?
Biogen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biogen?
Biogen paid dividends every year for the past 0 years.
What is the dividend of Biogen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biogen located?
Biogen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biogen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biogen from 4/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.
When did Biogen pay the last dividend?
The last dividend was paid out on 4/26/2024.
What was the dividend of Biogen in the year 2023?
In the year 2023, Biogen distributed 0 USD as dividends.
In which currency does Biogen pay out the dividend?
The dividends of Biogen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biogen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Biogen
Our stock analysis for Biogen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
